- Clear efficacy data for Cynata’s proprietary Cymerus™ MSCs in second preclinical study in a clinically-relevant model of asthma
- Cymerus MSCs caused significantly greater reduction of airway hyperresponsiveness compared to corticosteroid treatment
- Data suggest Cymerus MSCs can be administered alone or in combination with corticosteroids to treat the airway hyperresponsiveness associated with asthma
- Completion of this study will further advance the path towards clinical trials
MELBOURNE, Australia, Aug. 23, 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to announce further highly promising data supporting the efficacy of its proprietary Cymerus™ mesenchymal stem cells (MSCs) in a second preclinical asthma study.
The study was conducted under the supervision of Associate Professor Samuel and Dr Simon Royce of the Monash Lung Biology Network,1 focusing on the effects of CymerusTM MSCs in combination with or in comparison to the corticosteroid dexamethasone, which is commonly used to treat exacerbations of asthma in human patients. The study used a well-established mouse model of chronic allergic airways disease that closely resembles asthma in humans. This part of the study focused on airway hyperresponsiveness (AHR), which is a key clinical manifestation of asthma. [Read more…]